Health and Healthcare
Dendreon Gives Quarterly Report & Provenge Updates (DNDN)
Published:
Last Updated:
Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release. We had this on deck for a report this week and a conference call was set for Tuesday at 11:30 AM EST.
Dendreon’s total operating expenses were $20.929 million and net loss after items of $126.7 million after a $105+ million warrant item. That is not just from operations and it does include many ongoing or new items. That comes to a loss of $1.20 EPS and revenues were listed as $25,000.00.
More importantly, the company disclosed its expansion facilities and the associated costs in Georgia and in California. Dendreon is still expecting PROVENGE to be approved and it gave updates along those lines.
FULL DETAILS of the financial data and updates on Provenge are at BioHealthInvestor.com.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
